Outset Medical General Counsel to depart Sept. 2026

Outset Medical, Inc. (OM) reports that its General Counsel, John Brottem, has decided to depart from the company and his role, effective September 11, 2026, to pursue other professional opportunities.

Rhea-AI Filing Summary

Outset Medical, Inc. (OM) reports that its General Counsel, John Brottem, has decided to depart from the company and his role, effective September 11, 2026, to pursue other professional opportunities. The company states that his departure is not due to any dispute or disagreement with the company or its management.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Notice date of departure: August 27, 2026 Effective departure date: September 11, 2026 Common Stock par value: $0.001 per share

3 metrics

Notice date of departure August 27, 2026 Date John Brottem informed the company of his decision to depart

Effective departure date September 11, 2026 Effective date of General Counsel John Brottem’s departure

Common Stock par value $0.001 per share Par value of Outset Medical, Inc. common stock

Key Terms

General Counsel, Emerging growth company, Common Stock, $0.001 par value per share, Section 12(b)

4 terms

General Counsel regulatory

"his role as General Counsel, effective September 11, 2026"

A general counsel is the chief lawyer of an organization, responsible for overseeing all legal matters and ensuring the company complies with laws and regulations. Think of them as the organization's legal advisor or navigator, helping to prevent legal problems before they happen. Their role matters to investors because they help protect the company from legal risks that could impact its success and value.

Emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Common Stock, $0.001 par value per share financial

"Common Stock, $0.001 par value per share | | OM | | The Nasdaq Stock Market LLC"

Section 12(b) regulatory

"Securities registered pursuant to Section 12(b) of the Act"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Outset Medical (OM) disclose in this 8-K?

Outset Medical disclosed that its General Counsel, John Brottem, has decided to depart from the company and his role, effective September 11, 2026, to pursue other professional opportunities.

When is Outset Medical’s (OM) General Counsel John Brottem leaving the company?

Outset Medical states that General Counsel John Brottem will depart effective September 11, 2026, following his decision communicated to the company on August 27, 2026.

Did Outset Medical (OM) report any dispute related to John Brottem’s departure?

No. Outset Medical states that Mr. Brottem’s departure is not due to any dispute or disagreement with the company or its management.

What position did John Brottem hold at Outset Medical (OM)?

John Brottem served as General Counsel of Outset Medical, Inc. before informing the company on August 27, 2026 of his decision to depart.

On which exchange is Outset Medical (OM) listed and under what symbol?

Outset Medical’s Common Stock, $0.001 par value per share, is listed on The Nasdaq Stock Market LLC under the trading symbol OM.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:06 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:05 PM EDT Learn about SEC filing dates

0001484612false00014846122026-08-272026-08-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 27, 2026

Outset Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-39513	20-0514392
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
3052 Orchard Dr., San Jose, California		95134
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (669) 231-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		OM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 27, 2026, John Brottem informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company and his role as General Counsel, effective September 11, 2026, to pursue other professional opportunities. Mr. Brottem’s departure is not due to any dispute or disagreement with the Company or its management.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Outset Medical, Inc.
Date: August 28, 2026		By:	/s/ Renee Gaeta
			Renee Gaeta
			Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 29.2 KB